28 research outputs found
An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus
Background. A 2009 global influenza pandemic caused by a novel swine-origin H1N1 influenza A virus has posted an increasing threat of a potential pandemic by the highly pathogenic avian influenza (HPAI) H5N1 virus, driving us to develop an influenza vaccine which confers cross-protection against both H5N1 and H1N1 viruses. Previously, we have shown that a tetra-branched multiple antigenic peptide (MAP) vaccine based on the extracellular domain of M2 protein (M2e) from H5N1 virus (H5N1-M2e-MAP) induced strong immune responses and cross-protection against different clades of HPAI H5N1 viruses. In this report, we investigated whether such M2e-MAP presenting the H5N1-M2e consensus sequence can afford heterosubtypic protection from lethal challenge with the pandemic 2009 H1N1 virus. Results. Our results demonstrated that H5N1-M2e-MAP plus Freund's or aluminum adjuvant induced strong cross-reactive IgG antibody responses against M2e of the pandemic H1N1 virus which contains one amino acid variation with M2e of H5N1 at position 13. These cross-reactive antibodies may maintain for 6 months and bounced back quickly to the previous high level after the 2nd boost administered 2 weeks before virus challenge. H5N1-M2e-MAP could afford heterosubtypic protection against lethal challenge with pandemic H1N1 virus, showing significant decrease of viral replications and obvious alleviation of histopathological damages in the challenged mouse lungs. 100% and 80% of the H5N1-M2e-MAP-vaccinated mice with Freund's and aluminum adjuvant, respectively, survived the lethal challenge with pandemic H1N1 virus. Conclusions. Our results suggest that H5N1-M2e-MAP has a great potential to prevent the threat from re-emergence of pandemic H1N1 influenza and possible novel influenza pandemic due to the reassortment of HPAI H5N1 virus with the 2009 swine-origin H1N1 influenza virus. © 2010 Zhao et al; licensee BioMed Central Ltd.published_or_final_versio
Development of a Humanized HLA-A2.1/DP4 Transgenic Mouse Model and the Use of This Model to Map HLA-DP4-Restricted Epitopes of HBV Envelope Protein
A new homozygous humanized transgenic mouse strain, HLA-A2.1+/+HLA-DP4+/+ hCD4+/+mCD4−/−IAβ−/−β2m−/− (HLA-A2/DP4), was obtained by crossing the previously characterized HLA-A2+/+β2m−/− (A2) mouse and our previously created HLA-DP4+/+ hCD4+/+mCD4−/−IAβ−/− (DP4) mouse. We confirmed that the transgenes (HLA-A2, HLA-DP4, hCD4) inherited from the parental A2 and DP4 mice are functional in the HLA-A2/DP4 mice. After immunizing HLA-A2/DP4 mice with a hepatitis B DNA vaccine, hepatitis B virus-specific antibodies, HLA-A2-restricted and HLA-DP4-restricted responses were observed to be similar to those in naturally infected humans. Therefore, the present study demonstrated that HLA-A2/DP4 transgenic mice can faithfully mimic human cellular responses. Furthermore, we reported four new HLA-DP4-restricted epitopes derived from HBsAg that were identified in both vaccinated HLA-A2/DP4 mice and HLA-DP4-positive human individuals. The HLA-A2/DP4 mouse model is a promising preclinical animal model carrying alleles present to more than a quarter of the human population. This model should facilitate the identification of novel HLA-A2- and HLA-DP4-restricted epitopes and vaccine development as well as the characterization of HLA-DP4-restricted responses against infection in humans
Exploitation d’un modèle expérimentale préclinique de souris HLA transgénique pour l’identification des épitopes T HLA-restreint afin de concevoir des vaccins poly-epitopiques
A new homozygous humanized HLA transgenic mouse strain, HLA-A2.1+/+HLA-DP4+/+hCD4+/+mCD4-/-IAβ-/-β2m-/- (HLA-A2/DP4), was obtained by crossing the HLA transgenic HLA-A2.1+/+β2m-/-(A2) mice and HLA transgenic HLA-DP4+/+hCD4+/+mCD4-/-IAβ-/-(DP4) mice. In HLA-A2/DP4 mice, HLA-A2 restricted or HLA-DP4 restricted T cell responses against HBs antigen of hepatitis B virus after immunization with the HBsAg vaccine are similar to those induced in A2 mice, in DP4 mice, in HBV-infected or HBsAg-vaccinated humans. These results show that cellular responses induced in HLA-A2/DP4 mice faithfully mimic human responses counterparts. Thus, these mice represent an excellent animal model for preclinical experimentations to evaluate or compare the effectiveness of responses "human" induced in vivo by candidate vaccines. The model will also facilitate the identification of new epitopes HLA-A2 and HLA-DP4 restricted, which will be of future reactive for clinical monitoring response against infection in humans. By exploiting these HLA-A2/DP4 mice, we identified four new HLA-DP4-restricted epitopes from HBsAg and two new HLA-A2 restricted epitopes derived from protein M1.Une nouvelle lignée homozygote de souris « humanisé » HLA transgéniques : HLA-A2.1+/+HLA-DP4+/+hCD4+/+mCD4-/-IAβ-/-β2m-/- (HLA-A2/DP4), a été obtenue en croisant entre les souris HLA transgéniques HLA-A2.1+/+β2m-/-(A2) et les souris HLA transgéniques HLA-DP4+/+hCD4+/+mCD4-/-IAβ-/-(DP4). Chez les souris HLA-A2/DP4, les réponses cellulaire T HLA-A2 restreint ou HLA-DP4 restreint contre l’antigène HBs du virus de l’Hépatite B suite à une immunisation avec le vaccin anti-AgHBs sont similaires à ceux observés chez les souris A2, chez les souris DP4, chez les humains infectés par le virus ou immunisés avec le même vaccin. Ces résultats montrent que les réponses cellulaires induites les souris HLA-A2/DP4 miment fidèlement les réponses homologues humaines. Ainsi, ces souris représentent un excellent modèle d’expérimentations précliniques animal pour évaluer ou comparer l’efficacité des réponses « humain » induites in vivo par des candidates vaccins. Le modèle facilitera également l'identification de nouvelles épitopes HLA-A2 et HLA-DP4 restreints, qui constituera de futurs réactives de suivi clinique des réponses contre l'infection chez les humains.En exploitant ces souris HLA-A2/DP4, nous avons identifié quatre nouveaux HLA-DP4-restricted épitopes issus de l'AgHBs et deux nouveaux HLA-A2 restreint épitopes dérivés de protéines M1
Exploitation d un modèle expérimentale préclinique de souris HLA transgénique pour l identification des épitopes T HLA-restreint afin de concevoir des vaccins poly-epitopiques
Une nouvelle lignée homozygote de souris humanisé HLA transgéniques : HLA-A2.1+/+HLA-DP4+/+hCD4+/+mCD4-/-IAb-/-b2m-/- (HLA-A2/DP4), a été obtenue en croisant entre les souris HLA transgéniques HLA-A2.1+/+b2m-/-(A2) et les souris HLA transgéniques HLA-DP4+/+hCD4+/+mCD4-/-IAb-/-(DP4). Chez les souris HLA-A2/DP4, les réponses cellulaire T HLA-A2 restreint ou HLA-DP4 restreint contre l antigène HBs du virus de l Hépatite B suite à une immunisation avec le vaccin anti-AgHBs sont similaires à ceux observés chez les souris A2, chez les souris DP4, chez les humains infectés par le virus ou immunisés avec le même vaccin. Ces résultats montrent que les réponses cellulaires induites les souris HLA-A2/DP4 miment fidèlement les réponses homologues humaines. Ainsi, ces souris représentent un excellent modèle d expérimentations précliniques animal pour évaluer ou comparer l efficacité des réponses humain induites in vivo par des candidates vaccins. Le modèle facilitera également l'identification de nouvelles épitopes HLA-A2 et HLA-DP4 restreints, qui constituera de futurs réactives de suivi clinique des réponses contre l'infection chez les humains.En exploitant ces souris HLA-A2/DP4, nous avons identifié quatre nouveaux HLA-DP4-restricted épitopes issus de l'AgHBs et deux nouveaux HLA-A2 restreint épitopes dérivés de protéines M1.A new homozygous humanized HLA transgenic mouse strain, HLA-A2.1+/+HLA-DP4+/+hCD4+/+mCD4-/-IAb-/-b2m-/- (HLA-A2/DP4), was obtained by crossing the HLA transgenic HLA-A2.1+/+b2m-/-(A2) mice and HLA transgenic HLA-DP4+/+hCD4+/+mCD4-/-IAb-/-(DP4) mice. In HLA-A2/DP4 mice, HLA-A2 restricted or HLA-DP4 restricted T cell responses against HBs antigen of hepatitis B virus after immunization with the HBsAg vaccine are similar to those induced in A2 mice, in DP4 mice, in HBV-infected or HBsAg-vaccinated humans. These results show that cellular responses induced in HLA-A2/DP4 mice faithfully mimic human responses counterparts. Thus, these mice represent an excellent animal model for preclinical experimentations to evaluate or compare the effectiveness of responses "human" induced in vivo by candidate vaccines. The model will also facilitate the identification of new epitopes HLA-A2 and HLA-DP4 restricted, which will be of future reactive for clinical monitoring response against infection in humans. By exploiting these HLA-A2/DP4 mice, we identified four new HLA-DP4-restricted epitopes from HBsAg and two new HLA-A2 restricted epitopes derived from protein M1.PARIS11-SCD-Bib. électronique (914719901) / SudocSudocFranceF
An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus
Abstract Background A 2009 global influenza pandemic caused by a novel swine-origin H1N1 influenza A virus has posted an increasing threat of a potential pandemic by the highly pathogenic avian influenza (HPAI) H5N1 virus, driving us to develop an influenza vaccine which confers cross-protection against both H5N1 and H1N1 viruses. Previously, we have shown that a tetra-branched multiple antigenic peptide (MAP) vaccine based on the extracellular domain of M2 protein (M2e) from H5N1 virus (H5N1-M2e-MAP) induced strong immune responses and cross-protection against different clades of HPAI H5N1 viruses. In this report, we investigated whether such M2e-MAP presenting the H5N1-M2e consensus sequence can afford heterosubtypic protection from lethal challenge with the pandemic 2009 H1N1 virus. Results Our results demonstrated that H5N1-M2e-MAP plus Freund's or aluminum adjuvant induced strong cross-reactive IgG antibody responses against M2e of the pandemic H1N1 virus which contains one amino acid variation with M2e of H5N1 at position 13. These cross-reactive antibodies may maintain for 6 months and bounced back quickly to the previous high level after the 2nd boost administered 2 weeks before virus challenge. H5N1-M2e-MAP could afford heterosubtypic protection against lethal challenge with pandemic H1N1 virus, showing significant decrease of viral replications and obvious alleviation of histopathological damages in the challenged mouse lungs. 100% and 80% of the H5N1-M2e-MAP-vaccinated mice with Freund's and aluminum adjuvant, respectively, survived the lethal challenge with pandemic H1N1 virus. Conclusions Our results suggest that H5N1-M2e-MAP has a great potential to prevent the threat from re-emergence of pandemic H1N1 influenza and possible novel influenza pandemic due to the reassortment of HPAI H5N1 virus with the 2009 swine-origin H1N1 influenza virus.</p
Proliferative response in DP4-positive donors.
<p>*S181–S192 peptide was used as positive control.</p><p>The proliferation of CD4<sup>+</sup> T cells in 4 HBV vaccinated and 2 unvaccinated HLA-DP4<sup>+</sup> donors after <i>in vitro</i> stimulation with 5 newly identified HLA-DP4-restricted epitopes and one positive control peptide S181–S192. SI, stimulation index.</p
DP4 epitopes binding ability and proliferative response in HLA-A2/DP4 mice.
<p>Twelve HLA-DP4-restricted epitopes were predicted by scanning the entire HBs protein and were synthesized. Exp IC50 (nM) represents the predicted affinities according to algorithms, while Obs (nM) represents the affinities obtained from MHC class II binding assays. [<sup>3</sup>H]thymidine incorporation assays were used to measure the proliferation of CD4<sup>+</sup> T cells from DNA-vaccine-immunized HLA-A2/DP4 and H-2 class II-deficient mice stimulated with the twelve synthesized peptides, including the previously reported epitope, S181–192. Exp = Expected, Obs = Observed, SI, stimulation index.</p